Tag: CORO

Molnupiravir recommended only for those at highest risk for hospitalization given its potential long-term harms

VE increased for adolescents aged 16 to 17 years at seven or more days after a third booster dose during omicron predominance

Reactions to booster occur with similar frequency as after receipt of second vaccine dose, generally mild to moderate

Program to boost research into 'long COVID' has also been announced

Treatment of symptomatic COVID-19 with nirmatrelvir plus ritonavir linked to 89 percent lower risk for progression versus placebo

Two doses of BNT162b2 vaccine linked to high short-term protection against infection, which wanes after six months

Consider treatment with remdesivir for five days for hospitalized COVID-19 patients who do not require invasive ventilation or ECMO

Receipt of immunotherapy compared with no cancer treatment in the four weeks preceding COVID-19 diagnosis associated with lower mortality

Study showed 12 of 12 health care workers diagnosed with SARS-CoV-2 infection had at least mild symptoms

Secondary infection risks were lower for primary cases aged 12 to 17 years compared with those aged 18 to 49 years